IDH1 and glioma: Advancements in molecular testing have improved our understanding of the molecular categorization of gliomas, leading to a debate regarding whether GBM should be divided into isocitrate dehydrogenase (IDH)-mutant and IDH-wildtype subcategories (7, 8).